Hims & Hers Health (HIMS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.37
- Estimate
- -$0.05
- Surprise
- -640.0%
- Revenue (period 2026-06-30)
- $753.2M
- Score today
- 5.3/10
Revenue source: xbrl.
How the report landed
Hims & Hers Health (HIMS) reported a wider loss than forecast — adjusted EPS of -$0.37 against the -$0.05 estimate (a 640.0% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates HIMS Sell at 5.3/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -640.0% surprise compares with a -210.7% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- Concentration risk — Geographic: United States
- Target reached (-7.7% upside)
- Risk below floor (1.4 < 2.5)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $29.38
- Price target
- $31.17
- Stop
- $27.32
- Upside to target
- +6.1%
Risk check: trading volume is running 1.5× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-16 — shown for context, not personalized investment advice.
HIMS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $6.47B
- P/E (fwd)
- 37.6
- 52-week range
- $13.74–$63.63
- Off 52-week high
- 53.8%
- RSI (14)
- 50
- Volume vs avg
- 1.51×
- Score today
- 5.3/10